home / stock / mnpr / mnpr news

MNPR News and Press, Monopar Therapeutics Inc.

Stock Information
Company Name: Monopar Therapeutics Inc.
Stock Symbol: MNPR
Market: NASDAQ
Website: monopartx.com
Menu
MNPR MNPR Quote MNPR Short MNPR News MNPR Articles MNPR Message Board
Get MNPR Alerts

News, Short Squeeze, Breakout and More Instantly...
MNPR - Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appoi...
MNPR - Expected US Company Earnings on Friday, November 14th, 2025

Lifeward Ltd. (LFWD) is expected to report $-0.14 for Q3 2025 Bit Digital Inc. (BTBT) is expected to report $0 for Q3 2025 Scholar Rock Holding Corporation (SRRK) is expected to report $-0.88 for Q3 2025 Legence Corp. (LGN) is expected to report $0.03 for Q3 2025 TOMI Environmenta...

MNPR - Monopar Therapeutics GAAP EPS of -$0.48 misses by $0.05

2025-11-14 05:15:06 ET More on Monopar Therapeutics Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent Monopar Therapeutics announces pricing of $135M offering Monopar a new...

MNPR - Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments

WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quar...
MNPR - Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025

WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, is presenting new data and analys...

MNPR - Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025

WILMETTE, Ill., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that its abstract...

MNPR - Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted

2025-10-10 17:18:54 ET Shares of biopharmaceutical concern Monopar Therapeutics Inc. ( MNPR ) have had an absolutely massive surge in the past year after being left for dead with cash of $7.1 million and a market cap under $9 million. Its acquisition of Wilson disease candidate ALXN-184...
MNPR - US Companies Moving the Markets, Evening edition
Thu, Oct 02, 2025 as of 4:00 pm ET

A look at the top 10 most actives in the United States Aspire Biopharma Holdings Inc. (ASBP) rose 95.7% to $0.42 on volume of 629,172,711 shares Dragonfly Energy Holdings Corp (DFLI) rose 78.6% to $1.07 on volume of 338,116,050 shares Nuburu Inc. (BURU) rose 36.0% to $0.2212 on volume of 31...

MNPR - Outperform Recommendation Issued On MNPR By Oppenheimer

2025-10-02 10:15:13 ET Oppenheimer analyst issues OUTPERFORM recommendation for MNPR on October 2, 2025 11:50AM ET. The previous analyst recommendation was Outperform. MNPR was trading at $92.18 at issue of the analyst recommendation. The overall analyst consensus : BUY....

MNPR - Buy Recommendation Issued On MNPR By H.C. Wainwright

2025-09-29 09:15:09 ET H.C. Wainwright analyst issues BUY recommendation for MNPR on September 29, 2025 12:13PM ET. The previous analyst recommendation was Buy. MNPR was trading at $76.63 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...
Next 10